# Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT03439839** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

## Interventions

- **DRUG:** iptacopan
- **COMBINATION_PRODUCT:** Standard of Care

## Key facts

- **NCT ID:** NCT03439839
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2020-04-22
- **Final completion:** 2022-02-28
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03439839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03439839, "Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03439839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*